A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
A phase 3 trial of Entrectinib and Crizotinib in non-small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases is a phase 3 interventional study registered as NCT04603807 by Hoffmann-La Roche, with 217 participants enrolled, started 2021-09-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: Entrectinib and Crizotinib.
Similar pages
not linked directly; found by shared links- TrialStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Shares Entrectinib, Flatiron Health (Roche) and the tag pipeline.
- TrialDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Shares Flatiron Health (Roche), Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Shares Crizotinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares Flatiron Health (Roche) and the tag pipeline.